R&D Pipeline
Proprietary Diagnostics
Videssa® Breast: Cancer Blood Test
LymPro™: Alzheimer's Blood Test
TolloTest™: Coronavirus 3CL Protease Test
TBIA: AI Cancer Platform
Antiviral Drug Development
Tollovir™: 3CL Protease Inhibitor
Products & Services
Lab Solutions
Provista Diagnostics: CLIA/CAP Lab
COVID Testing: Lab Supplies & Automated Solutions
Dietary Supplement
Tollovid™: 3CL Protease Inhibitor
Insights
Publications
News & Media
Downloads
How It Works: 3CL Protease Inhibitors
Case Study: Lab Automation
Investors
About
Management Team
Board of Directors
Advisors
Career Opportunities
Add a button link here
Contact Us
All SEC Filings
Investors
Investors
Overview
News & Events
Press Releases
IR Calendar
Email Alerts
Company Info
Management Team
Presentations
Contacts
FAQ
Financial Info
Financial Results
Income Statement
Balance Sheet
Cash Flow
Stock Data
Quote
Charts
Historical Data
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Board of Directors
Governance Documents
Filing Type:
View All
10-K
10-Q
15-12G
20-F
20-F/A
3
4
424B4
6-K
6-K/A
8-A12G
8-K
8-K/A
CORRESP
D
DEF 14A
DEFA14A
DRS
DRS/A
DRSLTR
EFFECT
F-1
F-1/A
NT 10-K
NT 10-Q
NT 20-F
POS AM
PRE 14A
RW
S-1
S-1/A
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SEC STAFF ACTION
UPLOAD
Year:
View All
2023
2022
2021
2020
2019
2018
2017
2016
2015
Date
Form
Description
PDF
XBRL
Pages
07/17/23
15-12G
Notice of termination of registration of a class of securities under Section 12(g)
1
06/13/23
SEC STAFF ACTION
1
05/16/23
NT 10-Q
Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB
2
03/31/23
8-K
Current report filing
Documents
expand_more
EX-10.1
6
03/31/23
NT 10-K
Notice under Rule 12b25 of inability to timely file all or part of a Form 10-K, 10-KSB, or 10-KT
2
03/29/23
4
Statement of changes in beneficial ownership of securities
1
03/15/23
SC 13D/A
Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities
3
02/17/23
SC 13D
Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities
3
11/14/22
10-Q
Quarterly report pursuant to Section 13 or 15(d)
Documents
expand_more
EX-10.62
EX-10.63
EX-10.64
EX-10.65
EX-10.66
EX-31.1
EX-31.2
EX-32.1
EX-32.2
76
09/30/22
8-K
Current report filing
2
rss_feed
Filing RSS
1
2
3
4
5
6
7
8
9
10
…18
arrow_forward
Email Alerts
Company Profile
Contacts
RSS News Feed